The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age

INTRODUCTION: Interleukin-1 (IL-1) blockade is the treatment of choice of cryopyrin associated periodic syndromes (CAPS). Anti-IL-1 monoclonal antibody (canakinumab) was recently registered. However no clear data are available on the optimal schedule of administration of this drug. The aim of the pr...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Caorsi, Roberta, Lepore, Loredana, Zulian, Francesco, Alessio, Maria, Stabile, Achille, Insalaco, Antonella, Finetti, Martina, Battagliese, Antonella, Martini, Giorgia, Bibalo, Chiara, Martini, Alberto, Gattorno, Marco
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2013
Ämnen:
Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3672768/
https://ncbi.nlm.nih.gov/pubmed/23442610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/ar4184
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk